Purpose of review The Medicare Access and CHIP Reauthorization Act (MACRA) is a historic bill that was recently passed that establishes how quality measurement and practice patterns will affect physician reimbursement. Alternative payment models (APMs) are an essential component of MACRA and Medicare's vision of paying for highvalue care. This review describes APMs in the context of MACRA and their impact on urology.
INTRODUCTION
In an attempt to transition from paying for healthcare quantity to paying for high value care, Medicare and other commercial payers are increasingly turning to alternative payment models (APMs). 'Alternative payment model' is a broad term that defines several mechanisms by which payment moves away from the traditional fee-for-service structure, and links reimbursement more directly with quality and value in healthcare.
MEDICARE ACCESS AND CHIP REAUTHORIZATION ACT OF 2015
The Centers for Medicare and Medicaid Services (CMS) has a stated goal to have APMs be responsible for 50% of payments by the end of 2018 [1 & ]. In an effort to achieve this goal, on 14 October 2016, CMS released the final rule for the Medicare Access and CHIP Reauthorization Act (MACRA), a historic bill that permanently replaced the Sustainable Growth Rate [2] . This legislation had great bipartisan support and may be one of the most important set of legislative changes with regard to direct impact on physician payments in recent history. MACRA establishes how quality measurement and practice patterns will affect physician reimbursement and APMs are an essential component of MACRA.
MACRA affects all physicians who bill Medicare more than $30,000/year, provide care for greater than 100 Medicare beneficiaries per year and who have participated in Medicare prior to 2017. The bill also impacts advanced practitioners (physician assistants, nurse practitioners, clinical nurse specialists and certified nurse anaesthetists). Measurement will start 1 January 2017, but bonuses and penalties will not be awarded until 2019.
To start, eligible professionals will choose to be a part of one of two separate pathways: the MeritBased Incentive Payment System (MIPS) or APMs, between 1 January 2017 and 2 October 2017. Providers will collect data from 1 January 2017 to 31 December 2017. Bonuses and penalties will begin to be distributed by 1 January If participating in MIPS, providers will report performance data by 31 March 2018 and Medicare will provide performance feedback in 2018. Bonuses and penalties will begin to be distributed 1 January 2019.
MACRA and urology
How MACRA will affect urologists' remains unclear. What is clear is that the majority of urologists will be affected, with the potential for monetary gains or losses. Table 1 provides a summary of APMs and potential roles for Urologists. During the transition year, it is estimated that roughly 79.5% of providers will be covered under MIPS, with exclusions occurring for low volume (16.2%), newly enrolled in Medicare (3.6%) and qualifying (APM) participants (QPs, 0.8%). It is estimated that in 2019, under the standard scoring model, urologists will receive $11 million dollars for bonus payments, including exceptional performance outliers and will be responsible for $4 million dollars in penalties because of failing to participate, all together totalling 0.6% of allowed charges [5] .
Currently, APMs do not play a major role in urologists' practices. However, many hypothesize an increasing trend away from fee-for-service payment and towards APMs. In order to be successful under MACRA, better integration will be critical, with some theorizing that groups that are currently more integrated, such as those affiliated with the Large Urology Group Practice Association (LUGPA), will be better able to respond to MACRA than academic groups. However, others hypothesize that academic and larger private practices will respond similarly to the shift towards value and integration,
KEY POINTS
Medicare Access and CHIP Reauthorization Act (MACRA) establishes how quality measurement and practice patterns will affect physician reimbursement and APMs are an essential component of MACRA.
Alternative payment models (APMs) include Accountable Care Organizations (ACOs) and bundled payments.
Although APMs do not currently play a large role in urologists' practices, they will likely become more relevant in the future, as both CMS and private payers are transitioning away from fee-for-service towards value-based payment.
Alternative payment models and urology Kaye et al. making the practice structures more analogous [6] . Furthermore, across specialty partnerships will be essential, and urologists will need to examine the full spectrum of health outcomes that may result from a surgical episode [7] . Moreover, practices will have to track quality metrics and be able to respond to the results accordingly. Some Urology practices are already developing protocols and surveying their own quality metrics, which may make for an easier transition to MACRA [6] .
ACCOUNTABLE CARE ORGANIZATIONS AS ALTERNATIVE PAYMENT MODELS
'Accountable care organization' is a general term that describes a payment model that attempts to tie payments to quality and value [8] . It is usually a provider-led organization, often with a primary care focus, but including specialists; and covers a population of people. The ACO is responsible for cost and quality improvements for an established population of patients [9] .
ACOs are one of the fastest growing APM entities. As of the end of January 2016, ACOs demonstrated a 12.6% growth over the previous year, with 838 ACOs in all 50 states and the District of Columbia. ACOs cover 28.3 million lives, and 22% of Medicare beneficiaries in 477 Medicare ACOs. However, ACOs include both public (Medicare and Medicaid) and commercial contracts, with a greater share of commercial contracts than government contracts (17.2 for commercial payers vs. 8.3 for Medicare þ2.9 for Medicaid ACO lives per payer in millions) [10] .
Potential unintended consequences for accountable care organizations
Although initial results demonstrated improved quality and cost savings with ACOs [11] , recent analyses suggest that Medicare ACOs may not actually reduce cost and yield significant improvements in quality [12, 13] . Without a significant shared savings, physicians may feel as though the practice changes required by their ACO may not be worth the trouble. In addition, most ACOs are large organizations and physician participants may feel disconnected from the decisions that are made by their ACO leadership. Physician engagement will be essential for the success of ACOs.
Accountable Care Organizations and MACRA
Under MACRA, ACOs that meet the previously described APM criteria, will be considered 'Advanced' or 'Qualified' APMs and will be eligible for the resultant gains (or losses). Those ACOs that do not meet the required criteria will be subject to MIPs.
Accountable Care Organizations and urology
Only 10% of urologists (1118) are MSSP ACO participants [14] . However, 50% of the original MSSP ACOs had at least one urologist participating in its organization (and up to 55). Groups that included urology providers had more total number of providers and covered a larger number of beneficiaries than those that did not include an urologist [14] . Although most APMs are currently primary care focused, CMS' goal is to have more models applicable to specialty groups in the future [7] . As a part of this goal, MACRA created a Physician-Focused Payment Model Technical Advisory Committee, which is a board composed of 11 physicians, who are tasked with the goal of reviewing submissions for new APMs and submitting recommendations to the HHS Secretary.
In the future, in order for urologists to realize gains under MACRA, costs, savings and quality measures will be increasingly measured and it will be important for urologists to analyse high cost events and if care could be improved in a more cost-efficient manner. Furthermore, urologists will likely see more care transition to clinics, rather than emergency room visits; outpatient procedures will more likely be done in clinic settings, and procedures will be more likely to be performed in outpatient centres, rather than as inpatients, if appropriate. It will also be necessary to avoid great variability in treatment and costs and it will be critical to participate in more care coordination with primary care providers and other specialists [9] .
EPISODE-BASED BUNDLED PAYMENTS
Bundled payments are another potential mechanism by which a provider can realize gains from APM participation under MACRA. Bundled payments occur when a single entity is held financially responsible for all services in a given period of time. In a traditional sense, a bundled payment is a lump sum payment for hospitalization costs, physician costs and postacute care costs; but in reality, it is usually done through retrospective reconciliation and may or may not include all of the costs in the acute and postacute phase of the healthcare service.
Bundled payments started in 1983, with the kidney transplant bundle at UCLA [15] . Medicare entered the bundle payment market in 1991, where four hospitals participated in the 'Medicare Participating Heart Bypass Center Demonstration'. During this demonstration project, Medicare paid one fee for the inpatient hospital fee, physician services and any readmissions related to the surgery. This demonstration expanded to seven hospitals and continued until 1996.
Current demonstration programs
Currently, the Centers for Medicare and Medicaid Innovation (CMMI) is piloting four models of care, under its Bundled Payment for Care Improvement (BPCI) Initiative [16] . Model 1 is a single payment for a hospital admission, which does not include physician services. All Severity-Diagnosis Related Group (MS-DRG)s are included in the bundle. Model 2 is a retrospective payment wherein participants choose from 48 clinical care episodes. The bundle is based on inpatient and postacute care and related services for 90 days. Actual expenditures are compared with target prices and gains or losses are realized. Model 3 is similar to model 2, but only includes postinpatient care at a skilled nursing facility or using home healthcare. Model 4 is a single bundled payment, including physician services, for an entire hospital stay. In this model, participants also choose from 48 clinical care episodes.
The Oncology Care model is another bundled payment, wherein participants receive regular Medicare FFS payments as well as an additional 2 part payment system: a per-beneficiary Monthly Enhanced Oncology Services (MEOS) payment for care coordination and a performance-based payment for each care episode, which is calculated retrospectively on a semi-annual basis. The bundle is loosely defined and includes both Medicare and commercial payers.
Mandatory bundled payments
In addition to these demonstration programs, Medicare currently has several mandatory programmes. These include the CJR model and the Bundled Payment Model for Cardiac Care.
CJR was initially started on 1 April 2016. After 1 January 2019, practices participating in CJR will assume downside risk for care episodes. Practices can choose to accept downside risk as early as 1 January 2018, so that they can be Advanced APM participants under MACRA.
Payment includes all charges for an episode of care for diagnosis codes MS-DRG 469 or 470. The payment begins with the inpatient surgery and ends Alternative payment models and urology Kaye et al. 90 days after discharge and includes all services covered under Medicare Parts A and B. Each year, Medicare will release benchmark prices for each MS-DRG. Hospitals will be paid on a fee-for-service basis prospectively, but actual spending will be compared with Medicare's target, and bonuses will be rewarded or repayments made on the basis of cost and quality and the benchmark price. Participation is mandatory for and limited to hospitals located in 67 geographic areas (Metropolitan Statistical Areas). Initially, this bundle only included total hip and knee replacements, but it now includes surgeries to repair hip and femur fractures [17] . The Bundled Payment Model for Cardiac Care includes the Acute Myocardial Infarction (AMI) model and the coronary artery bypass graft (CABG) bundle. These are retrospective, 90-day bundles, wherein the fee-for-service payment is set against a benchmark. The bundles will begin on 1 July 2017 and are expected to run through 31 December 2021. Downside risk will begin performance year 3. There will be additional incentives for patients to receive cardiac rehab services after hospital discharge. CMS will initially randomly select hospitals for mandatory participation. These models will also qualify as Advanced APMs under MACRA.
Potential unintended consequences for bundled payments
Physicians have several concerns about bundled payments. First, as current bundled payment programmes do not incorporate robust risk-adjustment, physicians who treat medically complex patients may be unfairly penalized [18] . Second, the implementation of bundled payments may lead to an undue administrative burden for practices. For example, it will be difficult for a practice to understand how to do well in a bundled payment programme without sophisticated analytics. Finally, physicians may feel a loss of autonomy in their ability to order tests that may be expensive, but clinically necessary [19] .
Bundled payments and urology
There are currently no urology-specific bundled payments, but many theorize that they are likely to be initiated in the future. Both the American Urologic Association (AUA) and LUGPA are currently working on creating episodes of care. In fact, the AUA has an APM workgroup, which is working with the American College of Surgeons (ACS) on creating APMs for prostatectomy and nephrectomy [20] . LUGPA has partnered with Integra Connect to create urology-specific APMs [21] .
THE FUTURE OF ALTERNATIVE PAYMENT MODELS
At the time of writing this manuscript, the fate of the Affordable Care Act (ACA) has yet to be determined. Principles such as paying for increased value, healthcare transparency and patient access to data are long-standing and held true prior to the inception of the ACA [22] . Although the current administration promised to eliminate the ACA during the presidential campaign, MACRA embodies many of these values and was passed with great bi-partisan support, so is unlikely to change. However, CMMI was created as a part of the ACA and has been responsible for devising and evaluating Medicare's APMs. As the values on which CMMI is based have bi-partisan support, and the goal of CMMI is decreased domestic spending, it is also less likely that it will be discontinued [22] . Furthermore, the move away from traditional FFS towards value is occurring outside of the ACA and government programs and thus the trend, regardless of what happens with the ACA, will likely continue.
In contrast, changes may be realized with the mandatory nature of bundled payment, as the Health and Human Services (HHS) secretary, Tom Price, was leading the effort to eliminate mandatory bundled payments prior to his confirmation. However, only time will tell what changes will truly come with the new administration.
CONCLUSION
APMs are playing a critical role in the United States transformation of paying for healthcare quantity to a system paying for increased value. MACRA is accelerating the role of APMs in the healthcare system, but growth in APMs is occurring outside of MACRA as well and is also being driven by commercial payers. It will be important for urologists to track and respond to quality measures and increase care coordination, both goals of APMs, in order to succeed under MACRA.
